Close

UK To Give Faster Clinical Trial Nods Following Setbacks

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

The UK government intends to make clinical trials more accessible in order to re-establish the country’s reputation as a favoured location for pioneering research.

In a new initiative to jump-start the country’s faltering life sciences goals, the Medicines and Healthcare Products Regulatory Agency, plus research ethics reviews, could be integrated into making application processes faster for pharmaceutical manufacturers attempting to bring new medications to patients.

It is a critical policy among others proposed by the government, and it marks the most significant revision of clinical trial legislation in the UK in more than 20 years.

According to research published last year by the Association of the British Pharmaceutical Industry, the number of clinical trials initiated in the UK declined by 41% between 2017 and 2021, and it also zeroed in on the fact that studies were starting at a slower pace.

Over 2,000 comments to the consultation were contributed from around the world by patients, researchers, healthcare professionals, industry trade organizations, academic institutions, as well as individual pharmaceutical businesses.

Other proposed changes include assessing applications within 30 days, eliminating redundant regulations, and allowing studies with risks comparable to regular medical care to be permitted without regulatory approval. The government will also provide recommendations on trial diversity without imposing the possibility of targets or quotas.

The measures come only days after Chancellor of the Exchequer Jeremy Hunt announced plans to expedite drug approval. In the budget, the government allocated to the MHRA, the UK pharmaceuticals regulator, £10 million, approximately $12 million to explore collaborations with agencies overseas, including those in the US, Japan, and across Europe, to grant approval to drugs that have previously been approved elsewhere.

Latest stories